Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 64 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Pipeline Review, H2 2016', provides in depth analysis on Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted pipeline therapeutics. 

The report provides comprehensive information on the Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) 
- The report reviews Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents 2
List of Tables 5
List of Figures 5

Introduction 6
Global Markets Direct Report Coverage 6
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) Overview 7
Therapeutics Development 8
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Products under Development by Stage of Development 8
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Products under Development by Therapy Area 9
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Products under Development by Indication 10
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Products under Development by Companies 14
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Products under Development by Universities/Institutes 17
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Therapeutics Assessment 19
Assessment by Monotherapy/Combination Products 19
Assessment by Mechanism of Action 20
Assessment by Route of Administration 21
Assessment by Molecule Type 22
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Companies Involved in Therapeutics Development 24
4SC AG 24
Beactica AB 25
F. Hoffmann-La Roche Ltd. 26
GlaxoSmithKline Plc 27
Incyte Corporation 28
Oryzon Genomics SA 29
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Drug Profiles 30
4SC-202 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
GSK-2879552 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
IMG-7289 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
INCB-59872 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
ORY-2001 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
ORY-3001 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
RG-6016 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
RN-1 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecules 1 to Inhibit LSD1 and LSD2 for Oncology - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Small Molecules to Inhibit LSD-1 for Oncology - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecules to Inhibit LSD1 for Alzheimer's Disease, Oncology and Viral Infections - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
SP-2509 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
SP-2528 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
SP-2577 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Synthetic Peptide to Inhibit LSD-1 for Oncology - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Dormant Projects 50
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Featured News & Press Releases 53
Sep 12, 2016: Oryzon to Present ORY-2001 Preclinical Efficacy Data in Multiple Sclerosis Animal Model at ECTRIMS-2016 Annual Meeting 53
Jul 27, 2016: Oryzon Initiates Multiple Ascending Dose Cohorts in ORY-2001 Phase 1 Clinical Trial 54
Jul 05, 2016: Oryzon Nominates ORY-3001, a Specific LSD1 Inhibitor, Next Drug Candidate to Enter Preclinical Development in Non-Oncological Indications 54
Apr 11, 2016: Data on ORY-1001 to Be Presented at the AACR Annual Meeting 2016 in New Orleans 55
Apr 04, 2016: ORYZON Announces First Subject Dosed in Phase I Healthy Volunteer Study Evaluating Oral Epigenetic drug ORY-2001 for Alzheimer's Disease 56
Mar 21, 2016: Epigenetic compound 4SC-202 strengthens endogenous immune response to cancer 56
Jan 29, 2016: Oryzon Receives Approval in Spain to Initiate Phase I for ORY-2001 for Alzheimer's Disease 57
Dec 29, 2015: Oryzon Genomics Receives 1.3M USD Public Aids to Advance Development of its Epigenetic Inhibitors 57
Dec 16, 2015: ORYZON Files Clinical Trial Application in Spain for Phase I Study with ORY-2001 for Alzheimer's Disease 58
Dec 07, 2015: Imago BioSciences Announces Preclinical Data on LSD1 Inhibitor at Annual Meeting of the American Society of Hematology 59
Nov 10, 2015: Oryzon Genomics Announces First Patient Dosed in Phase I Extension Cohort of ORY-1001 59
Nov 02, 2015: Oryzon Announces Oral Presentation on ORY-2001 at 8th Annual Clinical Trials on Alzheimer's Disease Conference 60
Sep 30, 2015: 4SC receives funding from the Eurostars programme for further research of its anti-cancer agent 4SC-202 with an epigenetic mode of action 61
Sep 08, 2015: ORYZON Achieves Milestone in the Clinical Development of ORY-1001 61
Aug 24, 2015: ORYZON to Present at the 15 Annual Biotech in Europe Forum for Global Partnering & Investment in Basel, Switzerland 62

Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2016 17
Products under Investigation by Universities/Institutes, H2 2016 18
Assessment by Monotherapy/Combination Products, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 20
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 23
Pipeline by 4SC AG, H2 2016 24
Pipeline by Beactica AB, H2 2016 25
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 26
Pipeline by GlaxoSmithKline Plc, H2 2016 27
Pipeline by Incyte Corporation, H2 2016 28
Pipeline by Oryzon Genomics SA, H2 2016 29
Dormant Projects, H2 2016 50
Dormant Projects (Contd..1), H2 2016 51
Dormant Projects (Contd..2), H2 2016 52